Nattokinase Market Size, Share & Industry Analysis, By Form (Powder, Liquid, and Others), By Source (Soy-based and Non-Soy-based), By Application (Nutraceuticals & Dietary Supplements, Functional Foods & Beverages, Pharmaceuticals, and Others), and Regional Forecast, 2026-2034

The global nattokinase market size was valued at USD 34.99 million in 2025 and is projected to grow from USD 36.13 million in 2026 to USD 46.67 million by 2034, exhibiting a CAGR of 3.25% during the forecast period.

The nattokinase market is driven by rising cardiovascular disease prevalence, consumer demand for natural supplements, an aging population, preventive healthcare trends, and the growth of the nutraceutical industry. Nattokinase is an enzyme derived from natto, a traditional Japanese fermented soybean food, known for its fibrinolytic activity that supports cardiovascular health by promoting healthy blood circulation and preventing blood clotting. It is classified as a serine protease enzyme, and its primary role is breaking down fibrin, a protein involved in blood clot formation. Today, it is available mostly as a dietary supplement (capsules, tablets, powders, softgels) and is also being studied for potential pharmaceutical applications.

Nattokinase Market Driver

Rising Risk of Cardiovascular Diseases (CVDs) to Fuel Nattokinase Market Growth

Cardiovascular diseases remain the most common cause of mortality all over the world, with 17.9 million deaths annually as reported by the World Health Organization (WHO). Of these, about 85% are caused by heart attack and stroke. Nattokinase, being a natural fibrinolytic enzyme, is well marketed as a preventive measure against thrombosis, blood clotting, and hypertension. The increased prevalence of high blood pressure and rising numbers of disorders related to blood clots demand a strong market for natural circulatory wellness supplements such as nattokinase.

Nattokinase Market Restraint

Lack of Regulatory Approval and Standardization to Hinder Market Growth

One of the biggest challenges in the nattokinase market is the absence of formal regulatory approval in many regions. For instance, the U.S. Food and Drug Administration (FDA) has not licensed nattokinase as a medication to treat cardiovascular disease; it is available solely as a food supplement. Likewise, the European Food Safety Authority (EFSA) strictly regulates health claims, and nattokinase has not yet been approved for use in cardiovascular-related health claims. This regulatory ambiguity prohibits manufacturers from marketing the enzyme's benefits freely, reducing consumer familiarity and acceptance. Furthermore, there is no international standardization of dosage or potency, so product quality is highly inconsistent between brands.

Nattokinase Market Opportunity

Expansion of Nutraceuticals and Functional Foods to Pave New Opportunities

The nutraceuticals market is growing exponentially across the globe. According to the U.S. Food and Drug Administration (FDA), spending on dietary supplements and functional foods by consumers continues to grow steadily, with vitamins, minerals, and enzyme-based supplements among the most rapidly growing categories. Nattokinase is largely sold as a dietary supplement in capsule or powder dosage, but it is being integrated into functional foods and fortified beverages as well. Easy access through e-commerce websites (Amazon, iHerb, local supplement shops) has further increased global access, driving market growth.

Segmentation

Key Insights

The Report covers the following insights:

• Overview of the Parent Market
• Supply Chain Analysis
• Regulatory Landscape
• Recent Industry Development – New Product Launches, Mergers & Acquisitions, Investments, and Others
• Impact of Tariffs on the Market

Analysis by Form

By form, the market is divided into powder, liquid, and others.

The powder market leads in the global nattokinase market due to being the most convenient and universal form to be used in dietary supplements. Nattokinase powder is simple to process into tablets, capsules, and bulk supplement blends, which are the most common forms consumed by healthy adults and older individuals for cardiovascular health. It also possesses higher stability and shelf life in comparison to liquid products, making it preferable for distribution globally.

The liquid form is the fastest-growing category with increasing consumer demand for convenience, rapid absorption, and enhanced bioavailability. Liquid and softgel products are favored increasingly, especially in Asia and North America, with the increasing popularity of functional drinks and liquid nutraceuticals. The increasing popularity of e-commerce and upscale supplement segments is also driving the demand for liquid nattokinase products.

Analysis by Source

By source, the market is divided into soy-based and non-soy-based.

The soy-based segment dominates the global nattokinase market due to the fact that nattokinase is naturally digested from natto (fermented soybean), which has been historically consumed in Japan and is currently the most established, cost-efficient, and commercially available source. Its historical safety record, established fermentation technology, and consumer confidence in soy-based nutraceuticals are why it is currently the top category.

The non-soy-based segment is the fastest growing as manufacturers explore microbial fermentation and recombinant production methods to cater to consumers with soy allergies, dietary restrictions, or those seeking vegan/clean-label alternatives. With an estimated 0.4% of Americans and greater percentages in certain markets being allergic to soy, non-soy alternatives are on the rise, especially among Western consumers, where plant-based and allergen-free supplements are popular.

Analysis by Application

By application, the market is divided into nutraceuticals & dietary supplements, functional foods & beverages, pharmaceuticals, and others.

The nutraceuticals & dietary supplements segment dominates the global nattokinase market as nattokinase is largely promoted and used as a natural cardiovascular wellness supplement, particularly in powder and capsule form. It is largely distributed across pharmacies, health stores, and websites, from where consumers buy it for preventive medicines such as blood pressure management, circulation boosters, and cardiovascular well-being. Its legal categorization as a dietary supplement in the majority of the world's nations also renders it simpler to commercialize than drugs.

The pharmaceutical segment is the fastest growing, as increasing clinical studies investigate nattokinase’s potential in treating hypertension, thrombosis, and stroke prevention. With cardiovascular diseases causing 17.9 million deaths every year (WHO), demand for natural, safer therapeutic agents is great. As evidence increases and the regulatory environment changes gradually, pharmaceutical applications will grow at a rapid pace, fueling growth in this segment.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and South America.

Asia Pacific leads the global market for nattokinase due to its origin in Japan, where natto has been consumed for centuries as a food component. Japan is still the biggest consumer and manufacturer, with strong cultural acceptance, an aging population, and high awareness of functional foods and natural heart medications. China and South Korea also took up nattokinase quickly, with expanding nutraceutical industries and preventive healthcare emphasis.

North America is the most dynamic market due to increased consumer demand for natural cardiovascular health supplements, fast-growing nutraceutical markets, and high e-commerce penetration. The Centers for Disease Control and Prevention stated that more than 57% of U.S. adults consume dietary supplements, and cardiovascular diseases are the number one cause of mortality in the U.S. Awareness and usage of nattokinase are gaining momentum, thus making the region the fastest-growing in the world.

Key Players Covered

• Japan Bio Science Laboratory Co., Ltd (Japan)
• Daiwa Pharmaceutical Co., Ltd. (Japan)
• Contek Life Science Co., Ltd. (Taiwan)
• Sungen Bioscience Co., Ltd. (China)
• Eiffel Biotech (China)
• Bioven Ingredients (India)
• Novozymes A/S (Denmark)
• Pharmanager Ingredients (France)
• Geneferm Biotechnology Co., Ltd. (Taiwan)
• NattoPharma ASA (Norwegian)

Key Industry Developments

• In September 2024, Japan Bio Science Laboratory CO., Ltd., a Japanese company developing and manufacturing functional health food and supplement ingredients, unveiled NSK-SD Nattokinase, its patented and highly studied nattokinase enzyme, at the SupplySide West event.
• In August 2024, Kirin Holdings and Takanofoods launched a new natto fermented soybean product called "Sugoi Natto Gold with Plasma Lactobacillus Sauce" in Japan. The new product contains a sauce packed with Lactococcus lactis strain Plasma, a bacterium purported to boost immune function.